Integrin targeting ligands and uses thereof
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for αvβ3 integrin and/or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5. Compositions that include integrin targeting ligands and methods of use are also described.
1 . An integrin targeting ligand comprising the structure of any of the following:
or a pharmaceutically acceptable salt thereof, wherein indicates the point of connection to a moiety comprising a cargo molecule, wherein the cargo molecule is an RNAi agent.
2 . The integrin targeting ligand of claim 1 , further comprising a polyethylene glycol linker having 2-20 ethylene oxide units.
3 . A composition comprising the integrin ligand of claim 1 , and a pharmaceutically acceptable excipient.
4 . A composition comprising the integrin ligand of claim 1 , wherein the RNAi agent is capable of inhibiting the expression of a target gene in a cell expressing an integrin.
5 . The composition of claim 4 , wherein the integrin is integrin αvβ3, αvβ5, or both αvβ3 and αvβ5.
6 . A method of delivering the RNAi agent to a cell expressing integrin αvβ3, αvβ5, or both αvβ3 and αvβ5, in a subject, the method comprising administering to the subject a composition of claim 4 .
7 . A method of delivering the RNAi agent to a cell or tissue of a subject in vivo, the method comprising administering to the subject a composition of claim 4 .
8 . A method of inhibiting the expression of a target gene in a cell that expresses integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and αvβ5, in vivo, the method comprising administering to a subject an effective amount of a composition of claim 4 .
9 . The method of claim 8 , wherein the target gene is EPAS1 (HIF2 alpha).
10 . The method of claim 9 , wherein the cell is a clear cell renal carcinoma tumor cell.